Can a popular diabetes drug help liver transplant patients control blood sugar?
NCT ID NCT05195944
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two diabetes medications, semaglutide and sitagliptin, in 58 adults who have had a liver transplant and have poorly controlled diabetes. The goal is to see which drug better lowers blood sugar and body weight. Participants will take the study drug daily for the trial duration, and all will continue standard post-transplant medications for life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toronto General Hospital
Toronto, Ontario, M5G 2N2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- FitBit coaching may help amputees walk more after surgery
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?